Skip to main content
. 2020 Mar 13;12(3):675. doi: 10.3390/cancers12030675

Figure 1.

Figure 1

Serum 25(OH)D3 predicts PFS in EGFR-mutant LUAD but not KRAS-mutant LUAD. Participants were divided into groups based on their serum 25(OH)D3 levels with the cut-off set at 30 ng/mL. Kaplan–Meier progression-free survival (PFS) analyses in combined EGFR- and KRAS-mutant cohort (A), KRAS-mutant (B), and EGFR-mutant (C) subsets are shown. (D) Forest plot of associations between PFS and serum 25(OH)D3/patient sex/tumor genotype.